BRVE
Braveheart Bio, Inc. Common Stock (BRVE)
Healthcare • NASDAQ • $19.25+3.26%
Key Fundamentals
- Symbol
- BRVE
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $19.25
- Daily Change
- +3.26%
- Market Cap
- $1.68B
- Trailing P/E
- N/A
- Forward P/E
- -9.40
- 52W High
- $32.00
- 52W Low
- $17.86
- Analyst Target
- $45.25
- Dividend Yield
- 0.00%
- Beta
- N/A
About Braveheart Bio, Inc. Common Stock
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Company websiteResearch BRVE on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.